Haosun Pharmaceutical
Haosun Pharmaceutical Co., Ltd., commonly referred to as Haosun, is a prominent player in the pharmaceutical industry, headquartered in China (CN). Established in 2001, the company has made significant strides in the development and manufacturing of high-quality pharmaceutical products, particularly in the fields of oncology and cardiovascular health. With a strong operational presence across Asia and expanding into global markets, Haosun is dedicated to innovation and excellence. The company’s core offerings include a range of generic and proprietary medications, distinguished by their rigorous quality standards and advanced research methodologies. Recognised for its commitment to improving patient outcomes, Haosun has achieved notable milestones, including several certifications and partnerships that enhance its market position. As a trusted name in pharmaceuticals, Haosun continues to contribute to the health and well-being of communities worldwide.
DitchCarbon Score
How does Haosun Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Haosun Pharmaceutical's score of 15 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Haosun Pharmaceutical's reported carbon emissions
Haosun Pharmaceutical, headquartered in CN, currently does not have available data on its carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. This lack of information suggests that the company may still be in the early stages of formalising its climate commitments or reporting on its carbon footprint. In the pharmaceutical industry, companies are increasingly recognising the importance of addressing climate change and reducing greenhouse gas emissions. As such, Haosun Pharmaceutical may benefit from establishing clear emissions reduction targets and engaging in sustainability initiatives to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Haosun Pharmaceutical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
